Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-24-047676
Filing Date
2024-04-24
Accepted
2024-04-24 16:59:04
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A copy_of_ovid_defa14a_202.htm DEFA14A 16701
2 GRAPHIC img229406264_0.jpg GRAPHIC 503131
3 GRAPHIC img229406264_1.jpg GRAPHIC 383246
  Complete submission text file 0000950170-24-047676.txt   1238104
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

EIN.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38085 | Film No.: 24871338
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)